In prostate cancer, AR activated the expression of several lncRNAs, such as ARLNC1, PCGEM1, and SOCS2-AS1, via binding to the androgen response element (ARE) sites in the lncRNA locus and promoting tumor progression [39–41]. Here, SOCS2 is linked to prostate carcinoma.